We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of female genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Integrated Image Analysis in High Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) represents the most lethal gynecologic malignancy and is the fifth leading cause of cancer-related deaths in women. Importantly, the global cancer death rate as a whole has dropped by 23% since 1991, yet death rates for patients with ovarian cancer have remained stagnant over the past two decades. Although patients with HGSOC show initial sensitivity to platinum-based chemotherapy, most recur and become progressively resistant to platinum-based chemotherapy and other subsequent treatments.
The high tumour heterogeneity of HGSOC is believed to be responsible for this phenomenon. Our team has developed novel ways to assess tumour heterogeneity on computed tomography (CT) images which are routinely performed for staging and response assessment in patients with HGSOC.
This retrospective study aims to evaluate whether advanced imaging markers such as (whole tumour volume, metric of inter- and intra-side heterogeneity) predict with clinical endpoints (i.e. progression-free survival) and correlate with biological tissue characteristics.
This retrospective study will analyse CT images of patients with HGSOC treated in 22 trial centres, which were prospectively included in the clinical ICON8 trial. Patient included in this clinical trial had regular CT examination before, during and after treatment. We will analyse anonymised CT images before the start of treatment, before surgery and at time of disease progression and extract imaging markers at each time point.
Demographic and clinical data will be provided by the ICON8 trial team (MRC).
The total duration of the study is five years.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
- No computed tomography images prior to start of treatment (chemotherapy or surgery). - Insufficient images quality (i.e. motion artefacts).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by Wellcome Trust .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 45752
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
